Transplantation Infection Clinical Trial
Official title:
Renal Sensing of the Acidifying Effect of Sulphur-containing Amino Acids: Consequences for the Relation Between Protein Intake and Blood Pressure in Renal Transplant Recipients
Short-term (1-year) results of renal transplantation are now excellent (over 95%). Long-term (10-year and longer) results are, however, still disappointing. Where most research has focused on immunosuppression and infections, the investigators hypothesize that due to poor homeostatic capacity and necessary use of immunosuppressive and other drugs, renal transplant recipients are much more susceptible to poor dietary habits and exposure to potentially toxic contaminants than people of the general population, and that this contributes to accelerated function loss of the graft and excess risk of premature mortality, both contributing to poor long-term results. This study is a biobank and cohort study which investigates this hypothesis.
Short-term (1-year) results of renal transplantation are now excellent (over 95%). Long-term
(10-year and longer) results are, however, still disappointing. Where most research has
focused on immunosuppression and infections, the investigators hypothesize that due to poor
homeostatic capacity and necessary use of immunosuppressive and other drugs, renal transplant
recipients are much more susceptible to poor dietary habits and exposure to potentially toxic
contaminants than people of the general population, and that this contributes to accelerated
function loss of the graft and excess risk of premature mortality, both contributing to poor
long-term results.
To investigate one part of this overarching hypothesis, the investigators wrote a project on
around the specific topic of the relation between dietary acid load, ammoniagenesis and its
potential influence on blood pressure. The investigators used this project to build a biobank
and cohort in which they can test additional hypotheses on the relation between diet,
contaminants and development of graft failure and the occurrence of mortality.
The investigators also included 300 healthy controls to compare diet, contaminant exposure
and biomarkers with the renal transplant recipients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05047406 -
Bacillus Clausii in Liver Transplantation
|
Phase 2 | |
Completed |
NCT02463214 -
Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients
|
N/A | |
Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
Completed |
NCT01808456 -
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
|
Phase 4 | |
Suspended |
NCT01301118 -
Graft Take and Microbiology in Burns
|
N/A | |
Completed |
NCT00610961 -
Induction Related BK Viremia in Renal Transplant Patients
|
Phase 4 | |
Recruiting |
NCT05215327 -
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
|
Phase 2 | |
Recruiting |
NCT05193058 -
Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
|
||
Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01471444 -
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
Enrolling by invitation |
NCT01349738 -
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants
|
N/A | |
Terminated |
NCT00473824 -
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
|
Phase 2 | |
Completed |
NCT00177801 -
Organ Transplant Infection Prevention and Detection Project
|
Phase 4 | |
Completed |
NCT01276457 -
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
|
Phase 3 | |
Completed |
NCT02328963 -
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
|
Phase 4 | |
Recruiting |
NCT04320303 -
CMV Infection and Immune Intervention After Transplantation
|
N/A | |
Active, not recruiting |
NCT01295645 -
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
|
Phase 2 | |
Completed |
NCT02329808 -
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
|
||
Completed |
NCT01471067 -
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT04579471 -
Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
|